Similar articles for PMID: 24238861

Year	Number of Results
1992	2
1993	2
1995	3
1996	3
1997	1
1998	5
1999	4
2000	3
2001	2
2002	6
2003	6
2004	1
2005	6
2006	11
2007	1
2008	4
2009	4
2010	7
2011	11
2012	11
2013	6
2014	7
2015	11
2016	13
2017	29
2018	10
2019	17
2020	16
2021	13
2022	11
2023	1
2024	0

1

Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone.

Bendadi F, de Koning TJ, Visser G, Prinsen HC, de Sain MG, Verhoeven-Duif N, Sinnema G, van Spronsen FJ, van Hasselt PM. Bendadi F, et al. J Pediatr. 2014 Feb;164(2):398-401. doi: 10.1016/j.jpeds.2013.10.001. Epub 2013 Nov 14. J Pediatr. 2014. PMID: 24238861 Free article.

2

Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.

Kassel R, Sprietsma L, Rudnick DA. Kassel R, et al. J Pediatr Gastroenterol Nutr. 2015 Jan;60(1):e5-7. doi: 10.1097/MPG.0b013e3182a27463. J Pediatr Gastroenterol Nutr. 2015. PMID: 23838819 No abstract available.

3

In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.

[No authors listed] [No authors listed] Med Lett Drugs Ther. 2016 Oct 10;58(1505):e132. Med Lett Drugs Ther. 2016. PMID: 27701365 No abstract available.

4

[Evolution of a case of tyrosinemia type I treated with NTBC].

Ros Viladoms J, Vilaseca Buscà MA, Lambruschini Ferri N, Mas Comas A, González Pascual E, Holme E. Ros Viladoms J, et al. An Esp Pediatr. 2001 Mar;54(3):305-9. An Esp Pediatr. 2001. PMID: 11262262 Spanish.

5

Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I.

Thimm E, Herebian D, Assmann B, Klee D, Mayatepek E, Spiekerkoetter U. Thimm E, et al. Mol Genet Metab. 2011 Feb;102(2):122-5. doi: 10.1016/j.ymgme.2010.11.003. Epub 2010 Nov 10. Mol Genet Metab. 2011. PMID: 21112803

6

LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.

la Marca G, Malvagia S, Materazzi S, Della Bona ML, Boenzi S, Martinelli D, Dionisi-Vici C. la Marca G, et al. Anal Chem. 2012 Jan 17;84(2):1184-8. doi: 10.1021/ac202695h. Epub 2011 Dec 29. Anal Chem. 2012. PMID: 22148291

7

Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome.

Couce ML, Dalmau J, del Toro M, Pintos-Morell G, Aldámiz-Echevarría L; Spanish Working Group on Tyrosinemia type 1. Couce ML, et al. Pediatr Int. 2011 Dec;53(6):985-9. doi: 10.1111/j.1442-200X.2011.03427.x. Pediatr Int. 2011. PMID: 21752152

8

Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.

Santra S, Baumann U. Santra S, et al. Expert Opin Pharmacother. 2008 May;9(7):1229-36. doi: 10.1517/14656566.9.7.1229. Expert Opin Pharmacother. 2008. PMID: 18422479 Review.

9

Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?

Koelink CJ, van Hasselt P, van der Ploeg A, van den Heuvel-Eibrink MM, Wijburg FA, Bijleveld CM, van Spronsen FJ. Koelink CJ, et al. Mol Genet Metab. 2006 Dec;89(4):310-5. doi: 10.1016/j.ymgme.2006.07.009. Epub 2006 Sep 27. Mol Genet Metab. 2006. PMID: 17008115

10

Nitisinone: new drug. Type 1 tyrosinemia: an effective drug.

[No authors listed] [No authors listed] Prescrire Int. 2007 Apr;16(88):56-8. Prescrire Int. 2007. PMID: 17458044

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

203 results

Results by year